The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessAbstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Iron Biology in Immune Function, Muscle Metabolism and Neuronal Functioning
Beard, J. L. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.568s · Cited by 1,134
Okonko, D. O., Grzeslo, A., Witkowski, T., Mandal, A. K. J., Slater, R. M., Roughton, M., Foldes, G., Thum, T., Majda, J., Banasiak, W., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.036 · Cited by 569
Self-citationExercise limitation in chronic heart failure: Central role of the periphery
Clark, A. L., Poole-Wilson, P. A., & Coats, A. J. S. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00323-3 · Cited by 524
Self-citationIron uptake and metabolism in the new millennium
Dunn, L. L., Rahmanto, Y. S., & Richardson, D. R. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.12.003 · Cited by 420
Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options
Tang, Y.-D., & Katz, S. D. (2006) · Circulation · doi:10.1161/circulationaha.105.583666 · Cited by 415
Toblli, J. E., Lombraña, A., Duarte, P., & Di Gennaro, F. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.029 · Cited by 415
Etiology of Anemia in Patients With Advanced Heart Failure
Nanas, J. N., Matsouka, C., Karageorgopoulos, D., Leonti, A., Tsolakis, E., Drakos, S. G., Tsagalou, E. P., Maroulidis, G. D., Alexopoulos, G. P., Kanakakis, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.034 · Cited by 403
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292
Opasich, C., Cazzola, M., Scelsi, L., De Feo, S., Bosimini, E., Lagioia, R., Febo, O., Ferrari, R., Fucili, A., Moratti, R., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi388 · Cited by 287
Massie, B. M., Conway, M., Rajagopalan, B., Yonge, R., Frostick, S., Ledingham, J., Sleight, P., & Radda, G. (1988) · Circulation · doi:10.1161/01.cir.78.2.320 · Cited by 268
[Intravenous iron-dextran: therapeutic and experimental possibilities].
Ganzoni, A. M. (1970) · PubMed · Cited by 247
Davies, K. J., Maguire, J. J., Brooks, G. A., Dallman, P. R., & Packer, L. (1982) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1982.242.6.e418 · Cited by 165
Usmanov, R. I., Zueva, E. B., Silverberg, D. S., & Shaked, M. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.236 · Cited by 130
Anker, S. D., Colet, J. C., Filippatos, G. S., Willenheimer, R. B., Dickstein, K., Drexler, H., Lüscher, T. F., Mori, C., Rothe, B. V. E., Pocock, S., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp140 · Cited by 130
Self-citationRestless Legs Syndrome: Pathophysiology, Diagnosis and Treatment
Satija, P., & Ondo, W. G. (2008) · CNS Drugs · doi:10.2165/00023210-200822060-00004 · Cited by 85
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Self-citation
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.